The Effect of Antivascular Endothelial Growth Factor Therapy on the Development of Neovascular Glaucoma after Central Retinal Vein Occlusion: A Retrospective Analysis
Table 3
Ischemic CRVO eyes with ocular NV.
Patient
NV type
Total anti-VEGF doses received
Average interval between anti-VEGF doses (mos)
Duration symptom onset to NV diagnosis (mos)
Duration from symptom onset to PRP delivery (mos)
NVG
Duration from symptom onset to NVG diagnosis (mos)
